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In the book Epidemiology of Diabetes and Its Vascular Lesions (1978), Kelly West summarized
extant knowledge of the distribution and causes of diabetes. The 30 years of epidemiological
research that followed have seen remarkable advances in the understanding of obesity as a risk
factorfortype2diabetes,anddiabetesandpre-diabetesasriskfactorsforcardiovasculardisease.
Increasinglydetailedunderstandingoftheserelationshipshas,unfortunately,beenaccompanied
by an alarming increase in the prevalence of obesity, diabetes, and cardiovascular disease. West
recognized that pre-diabetes is recognizable as what we now call metabolic syndrome. He
predicted that novel insight into diabetes pathogenesis would come from biochemical and
genetic epidemiology studies. He predicted that type 2 diabetes could be prevented by healthy
lifestylechange.Thechallengenowisforustotranslatetheseinsightsintoeffectivestrategiesfor
the prevention of the modern epidemic of diabetes and vascular disease.
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I
n his landmark book, Epidemiology of
Diabetes and Its Vascular Lesions (1),
Kelly West reviewed and summarized
the extant scientiﬁc knowledge relevant
to the distribution and causes of type 1
and type 2 diabetes. Epidemiology of Dia-
betes was published in 1978. The meth-
odological foundations of modern
epidemiology and clinical trials had been
laid, and on these foundations West con-
solidated the major questions that we
have sought to answer over subsequent
decades. West recognized that obesity,
type 2 diabetes, and cardiovascular dis-
ease (CVD) are intimately linked. He
pointed out that the state of pre-diabetes
is readily identiﬁable, and that type 2 di-
abetesshouldbepreventable.Hehypoth-
esized that new biochemical and genetic
markers of diabetes risk would be identi-
ﬁed and reveal mechanisms linking obe-
sity, type 2 diabetes, and CVD. Most
importantly, he emphasized that the sci-
enceofclinicalepidemiologyprovidesthe
foundation for the prevention of diabetes
and its vascular complications.
The Framingham Heart Study (FHS),
a longitudinal, multigenerational cohort
studyofCVDanditsriskfactors,haspro-
vided a rich resource to address the ques-
tions raised by West. Despite the fact that
theFHSparticipantsaremostlywhiteand
of European ancestry, their health experi-
ence reﬂects the health experience of
other populations in the U.S. and other
developed countries around the world.
The prevalence of obesity (BMI 30 kg/
m
2) in FHS has risen inexorably in both
men and women over the past 30 years
from just a few percent among men in the
1970s to 25–30% among men in the
1990s (Fig. 1A) (2). A similar trend oc-
curred in women. Over the same time
frame,theprevalenceoftype2diabetesin
FHS rose steadily (Fig. 1B) (3). Alarm-
ingly, virtually the entire rise in type 2
diabetes has occurred in individuals with
obesity, from about 6% in the 1970s to
over 12% in the 1990s. This association
clearly demonstrates that the widespread
rise in obesity is pushing a rising tide of
type 2 diabetes. West was among the ﬁrst
to strongly emphasize that CVD is the
principal cause of morbidity and mortal-
ity in type 2 diabetes. Although the abso-
lute risk of CVD in FHS (deﬁned by fatal
and nonfatal myocardial infarction,
stroke, and intermittent claudication) has
declined between the 1950s and the
1990s by 35% in people without diabetes
and by 49% in those with diabetes, the
relative risk among those with diabetes to
develop CVD has persistently remained
about twofold higher relative to those
without diabetes (4). The rising preva-
lence of type 2 diabetes, combined with a
constant relative risk for CVD, has trans-
lated into a 60% increase in the attribut-
able risk ratio for CVD associated with
diabetes, even while the attributable risk
for CVD associated with other risk factors
like hypertension and smoking has held
constant or fallen (Fig. 1C) (5). Again the
experienceofFHSshowsusthattherising
tide of obesity is pushing a rising tide of
type 2 diabetes, which in turn is pushing
a rising tide of CVD and death. West en-
visioned this, and the challenge for pre-
vention is clear.
From a clinical perspective, CVD is
often viewed as a consequence of diag-
nosed type 2 diabetes. However, the ex-
perience of FHS and other cohorts has
shown that pre-diabetes (deﬁned by
blood glucose levels below the diagnostic
threshold for diabetes, but nonetheless
notnormal)isalsoassociatedwithriskfor
cardiovascular disease (6). This observa-
tion has given rise to the notion that type
2 diabetes and CVD may share a common
pathogenesis. Indeed, these diseases
share many common risk factors, includ-
ing obesity (especially central obesity),
hyperinsulinemia (reﬂecting, in part, in-
sulinresistance),hyperglycemia,adyslip-
idemiacharacterizedbylowlevelsofHDL
cholesterol and elevated levels of triglyc-
erides, and elevated blood pressure.
These measurable clinical traits are inter-
correlated,co-occurtoafargreaterdegree
than would be expected by change alone,
and cluster together in an identiﬁable
pattern linked by obesity and insulin
resistance (Fig. 2A and B) (7,8). This phe-
nomenon of risk factor clustering is now
called, for better or worse, metabolic syn-
drome (Fig. 2C). There are a variety of
enthusiastically contested deﬁnitions of
metabolic syndrome; in FHS, the deﬁni-
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Education Program Adult Treatment
Panel III (NCEP ATPII) is the one most
often studied (9).
A fundamental hypothesis raised by
theconceptofmetabolicsyndromeisthat
its presence increases future risk for both
type 2 diabetes and CVD, even after ac-
counting for other disease-speciﬁc risk
factors. In FHS, metabolic syndrome in-
creases the 7- to 11-year risk for CVD in
men by about threefold relative to those
without metabolic syndrome, and for
type 2 diabetes, the increase is about sev-
enfold(Fig.3A)(10).Associationsamong
women are similar. Risk rises steadily in a
dose-responserelationshipasthenumber
of component traits increases. Further,
riskisincreasedregardlessofwhichofthe
various heterogeneous combinations of
speciﬁc traits are present and even in the
absence of impaired glycemia. For in-
stance, in individuals with the combina-
tion of low HDL cholesterol and elevated
triglyceridesandbloodpressurebutwith-
out impaired glycemia, the relative risk
for CVD is about twofold increased rela-
tive to those without this trait combina-
tion, and for type 2 diabetes, the relative
risk is 3.5-fold increased (Fig. 3B). The
data suggest that beyond the speciﬁc
risk factors that may be present, it is
something about the phenomenon of
risk factor clustering itself that appears
to account, at least in part, for subse-
quent disease risk. Metabolic syndrome
also accounts for some of the heteroge-
neity for future disease risk observed in
individuals with obesity. Among FHS
individuals with BMI 25 kg/m
2 who
meet the criteria for metabolic syn-
drome, the 7-year cumulative incidence
of type 2 diabetes was about 7%, while
among those with BMI 30 kg/m
2 but
without metabolic syndrome, the rate
was only about 3% (11). These individ-
uals can be considered to represent
“metabolically obese, normal weight”
and “metabolically healthy obese” sub-
phenotypes, respectively. Similar albeit
less dramatic patterns were seen for risk
of CVD. If there is one obvious lesson
that can be drawn from the studies of
metabolic syndrome, it is that that met-
abolic syndrome is a far more powerful
risk factor for type 2 diabetes than for
CVD.
Figure 1—Increasing rates of obesity are associated with increasing rates of diabetes, which in turn are associated with increasing rates of CVD in
FHS. A: Shows the dramatically rising 30-year mortality-adjusted cumulative incidence rate of obesity (BMI 30 kg/m
2) for men in different
age-groups; the experience was similar among women (adapted from Vasan et al. [2]). B: Shows that the 8-year incidence rate of diabetes increased
primarilyinthosewithobesity(amongbothmenandwomen)(adaptedfromFoxetal.[3]).C:Showsa1.6-foldincreaseovertimeintheattributable
risk percent for CVD associated with diabetes (arrows); among common CVD risk factors, only diabetes contributed signiﬁcantly to increased rates
of CVD (adapted from Fox et al. [5]). HTN, hypertension.
Figure 2—Type 2 diabetes and CVD risk factor clustering is called metabolic syndrome. A: Shows that the observed co-occurrence of two or more
of elevated fasting glucose (FG), fasting insulin (FI), triglycerides (TG), blood pressure (BP), BMI, or low HDL cholesterol (all deﬁned in A as the
extreme 20th percentile, light gray bars for women and dark gray bars for men) co-occur to a far greater degree than would be expected by change
alone (compared with a binomial distribution, dashed line, P  0.0001). B: Shows that the pattern of risk factor clustering for these risk factors
(including,aswell,glucoselevels2hafteranoralglucosetolerancetest[2-hG]andwaist-to-hipratio[WHR])representthreeclinicallyidentiﬁable
phenotypes:impairedglucosetolerance(IGT),hypertension(HTN),andcentralobesity-dyslipidemia,linkedtogetherbyobesity(inthisﬁgure,BMI)
and fasting hyperinsulinemia (reﬂecting, in part, insulin resistance). C: Illustrates that obesity and insulin resistance constitute the common
physiological antecedents leading to increased risk for the development of both type 2 diabetes (T2D) and CVD; the name currently applied to this
phenomenonismetabolicsyndrome.AandBareadaptedfromWilsonetal.(7)andMeigsetal.(8).DBP,diastolicbloodpressure;SBP,systolicblood
pressure.
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synonymous with pre-diabetes. This fact
has been exploited to develop highly reli-
able clinical prediction rules for type 2
diabetesriskprediction.InFHSandother
studies, the combination of age, sex, fam-
ily history of diabetes, and metabolic syn-
drome traits can correctly discriminate an
individual at risk to develop type 2 diabe-
tes in the next 7 years in about 85% of
cases (12). The majority of research on
outcomes associated with metabolic syn-
drome has been conducted in rigorously
phenotyped, formal epidemiological
studies like FHS. Nonetheless, risk factor
clustering deﬁned with imprecise pheno-
typing, such as is available in usual care
clinical data, effectively predicts adverse
outcomes. If medical records of patients
without clinical diabetes or CVD contain
any evidence of obesity or elevated blood
pressure, causal glucose, triglycerides, or
total cholesterol, those with none, one to
two,orthreeormoreofthesetraitshavea
3-year incidence of type 2 diabetes of 1.4,
4, and 11%, respectively (13). Incidence
rates of CVD are 3.1, 5.3, and 6.4%, an-
nualtotalmedicalcostsareabout$3,000,
$4,000, and $5,000, and inpatient
length-of-stayare4,5,and6days,respec-
tively. Despite increased risk for adverse
outcomes associated with risk factor clus-
tering, few patients have ever heard of
metabolic syndrome, those with risk fac-
tor clustering do not perceive themselves
to be at increased risk of type 2 diabetes,
and even those that do perceive them-
selvestobeatriskofdiabetesarenotmore
likely than those who do to have inten-
tions to adopt a more healthy lifestyle in
the coming year (14). Again, the chal-
lenge for prevention is clear. The concept
of risk factor clustering as embodied in
metabolic syndrome appears to afford a
readily available clinical approach to
identify individuals at elevated risk for
type 2 diabetes, CVD, and increased
health care costs and utilization. The
overall utility of metabolic syndrome has
been strongly contested, due, appropri-
ately, to the lack of direct evidence that it
arises from a unifying pathophysiology or
that its diagnosis alters clinical outcomes.
Itdoesseemtohaveobviousvalueforrisk
identiﬁcationandpreventionoftype2di-
abetes, but this remains to be tested for-
mally in a clinical trial.
The concept of metabolic syndrome
has lead to a vigorous search for molecu-
lar and physiological mechanisms to ex-
plain the phenomenon of risk factor
clustering.Abnormaladipocytesignaling,
impaired endothelial function, and sys-
temicsubclinicalinﬂammationhavebeen
hypothesized to play a role that uniﬁes
excess adiposity with insulin resistance,
impaired -cell function, and small and
large vessel arterial disease (15). The adi-
pocytokinesadiponectin,resistin,andtu-
mor necrosis factor- (TNF-) are all
associated with both obesity and insulin
resistance in free-living humans (16).
However, beyond these robust cross-
sectional associations, the inter-
relationships of adipokine biomarkers
with incident diabetes and CVD have
been difﬁcult to untangle. For instance,
low levels of adiponectin (but not resistin
or TNF-) are associated with the in-
creased risk for type 2 diabetes after ac-
counting for confounding risk factors
including obesity (17), whereas resistin
but not adiponectin are associated with
the risk for heart failure, and neither are
associatedwiththeriskforcoronaryheart
disease (18). Insulin resistance, on the
other hand, is associated in FHS and
many other studies with both type 2 dia-
betes and CVD, even after accounting for
confounding risk factors (19). Plasma bi-
omarkers of endothelial dysfunction in-
cluding levels of E-selectin, plasminogen
activator inhibitor-1 (PAI-1), and von
Willebrand factor are associated with the
risk for new cases of type 2 diabetes even
after considering concurrent obesity, im-
paired glycemia, family history of type 2
diabetes, and other common risk factors
(Fig. 4A) (20,21). Plasma levels of von
Willebrand factor antigen also predict in-
cidentCVD,especiallyinindividualswith
type 2 diabetes, pointing to endothelial
dysfunction as a risk factor common to
both type 2 diabetes and CVD and per-
hapsaunifyingfactorunderlyingriskfac-
tor clustering (Fig. 4B) (22).
For the most part, data to support ab-
normal adipokine signaling, endothelial
dysfunction,orinﬂammationascentralto
risk factor clustering come from observa-
tional studies, where bias or residual
Figure3—Metabolicsyndrome(MetS)isariskfactorforbothtype2diabetes(T2D)andCVD.A:ShowsthatamongmeninFHS,the7-to11-year
risk for CVD increases from 1.5 for those with one or two MetS risk factors (RFs) to 4.0 for those with three or more (that is, with MetS) relative to
those with no MetS risk factors, even after accounting for other CVD–speciﬁc risk factors. The bars in the ﬁgure represent the odds ratio and its 95%
conﬁdence bounds. The relative risk for CVD is 2.9 comparing MetS vs. no MetS. Risk for type 2 diabetes increases from 4.2 for men with one or two
MetS risk factors to 24 for those with MetS relative to those with no MetS risk factors, even after accounting for other type 2 diabetes–speciﬁc risk
factors. The relative risk for type 2 diabetes is 6.9 comparing MetS vs. no MetS. Patterns are similar for FHS women. Risk rises steadily in a
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ciations observed. Mendelian randomiza-
tion is a methodological approach that
has been proposed to address this prob-
lem, where genetic variants associated
with intermediate traits (for instance, adi-
ponectin) can be used as unconfounded
markersofriskfordiseaseendpoints(like
type 2 diabetes) associated with the inter-
mediate trait (23). The demonstration
that common genetic variants associated
with variation in LDL cholesterol levels
also increase the risk of coronary heart
disease provide proof-of-principal for the
approach(24).Inthecaseofadiponectin,
however, variants in regulatory regions of
ADIPOQ,thegene-encodingadiponectin,
are associated with variation adiponectin
levels, while a different coding variant in
ADIPOQ appears to be associated with
type 2 diabetes risk (25). It is not entirely
clear that in every instance Mendelian
randomization will allow observational
data to reveal causality. Indeed, West’s
vision that biochemical and genetic
markers of diabetes risk will reveal mech-
anisms linking obesity, type 2 diabetes,
andCVDhasprovedtobetrue.However,
deﬁning novel methods to deﬁne causal
links among the many factors that have
been discovered remains a puzzle yet to
be solved.
The dazzling pace at which genetic
risk factors for type 2 diabetes have been
discovered in recent years only adds to
the excitement and challenge in the
ﬁeld. Inexpensive, high-density single
nucleotide polymorphism (SNP) arrays
combined with extensive, careful phe-
notyping in large numbers of individuals
have opened a new era in genetic discov-
ery for common disease. In FHS, millions
of SNPs linked to thousands of traits in
over 8,000 individuals have been made
publicly available (with appropriate per-
missions) as the Framingham Heart
Study SNP Health Association Resource
(SHARe) at the National Center for Bio-
technology Information Genotypes and
Phenotypes (NCBI dbGaP) web site
(www.ncbi.nlm.nih.gov/projects/gap/
cgi-bin/study.cgi?idphs000007). At
least as exciting has been the collabora-
tion among FHS SHARe and similar stud-
ies to form large consortia for genetic
discovery. The Meta-Analysis of Glucose
and Insulin-related traits Consortium
(MAGIC), for instance, has pooled data
includingover120,000individualsofEu-
ropean ancestry without clinical diabetes
from over 50 cohort studies for collabo-
rative research involving over 300 inves-
tigators. Already, MAGIC has identiﬁed
16 common SNPs associated with levels
offastingglucose,fastinginsulin,andlev-
els of glucose 2 h after an oral glucose
tolerance test (26–28). Eleven of these
loci are completely novel and eight are
also associated with the risk for type 2
diabetes, suggesting some genetic control
over glucose homeostasis that is distinct
from genetic factors in type 2 diabetes
pathogenesis.Manynewlocicanbelocal-
ized to diverse aspects of -cell mass, life
span, and function. Several others have
revealed or conﬁrmed novel mechanistic
pathways underlying diabetes physiol-
ogy, including variants that localize in or
near genes involved in the Circadian
(MTNR1B, CRY2) and alpha-adrenergic
systems (ADRA2), fatty acid metabolism
(FADS1), and the incretin system (GIPR).
West would no doubt have been excited
by this demonstration of the awesome
power of large-scale epidemiology to re-
vealnovelaspectsoftype2diabetesphys-
iology and pathogenesis.
The possibility to use new biochemi-
cal and genetic discoveries for type 2 dia-
betes prediction and prevention would
perhaps have most intrigued West. It is
now possible for an individual to pur-
chase a diabetes genetic risk proﬁle from
several different companies for just a few
hundred dollars. However, the ability of
these proﬁles to discriminate future dis-
ease risk remains, at present, somewhat
uncertain. In FHS, a genetic risk score
comprised of 18 conﬁrmed type 2 diabe-
tes risk SNPs was higher among individ-
uals who developed type 2 diabetes over
28 years compared with those who re-
mained free of diabetes, although the ab-
solute magnitude of the difference was
minute (about 0.6 risk alleles, although
the probability that there was no differ-
ence was 0.0001) (Fig. 5A and B) (29).
Interestingly, both parental history of
type 2 diabetes and the genetic risk score
were independently associated with type
2 diabetes risk. This suggests both that
our genetic understanding of type 2 dia-
betes remains incomplete and that family
history,whichiscommonlyconsideredto
represent inherited genetic risk, likely
also represents behaviors and norms that
are learned and transmitted in families.
Figure 4—Plasma biomarkers of endothelial dysfunction predict both type 2 diabetes (T2D) and CVD. A: Shows the 7-year cumulative incidence
oftype2diabetesbyquartile(Q1-Q4)ofplasminogenactivatorinhibitor-1(PAI-1)orvonWillebrandfactor(vWF).Thetype2diabetes–riskfactor
adjusted relative risk (RR) for type 2 diabetes per interquartile (IQR) increase in vWF was 1.4 (95% CI 1.1–1.8, P  0.009) (adapted from Meigs
etal.[21]).B:ShowssurvivalfreeofCVDeventsinFHSasafunctionofthepresenceorabsenceoftype2diabetesandbylow(Q1-Q3)orhigh(Q4)
levels of vWF. Risk of CVD is increased in individuals with elevated levels of vWF, especially in individuals with type 2 diabetes and elevated vWF
(P  0.0001) (adapted from Frankel et al. [22]). DM, diabetes mellitus.
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substantivelyimproveriskdiscrimination
after considering characteristics that are
easily and commonly measured in a rou-
tine adult check-up, including age, sex,
family history of diabetes, and metabolic
syndrome traits (Fig. 5C). It appears that,
at present, reliance on these standard
phenotypic risk factors remains the best
way to identify individuals at increased
risk for future type 2 diabetes. However,
both physicians and patients place high
faith in the present and future ability of
genetic testing to improve type 2 diabetes
prevention and care (30). In a hypotheti-
cal scenario, 99% of patients with a ge-
netic test result indicating a high chance
of developing diabetes state that they
wouldbemoremotivatedtomakerecom-
mended lifestyle changes, while 59% of
those with a test result indicating low ge-
netic risk would be unmotivated or less
motivated to make recommended life-
stylechanges.Thisishighlyrelevantsince
healthy lifestyle change appears to reduce
thefutureriskoftype2diabetesinpeople
athighandlowdiabetesgeneticrisk(31),
and there is a very clear dose-response
relationship with long-term success with
healthy lifestyle change and the reduced
risk of type 2 diabetes (32). These obser-
vations raise the compelling hypothesis
that genetic knowledge could be lever-
aged to improve motivation and adher-
ence to type 2 diabetes prevention
interventions.
The 30 years of epidemiology and
clinical trials research that have followed
thepublicationofEpidemiologyofDiabetes
and Its Vascular Lesions have seen remark-
ableadvancesinourunderstandingofthe
importance of obesity as a risk factor for
type2diabetes,andoftype2diabetesand
pre-diabetes as risk factors for CVD. De-
spite increasingly detailed biochemical
and genetic understanding of these rela-
tionships, the past 30 years have seen an
alarming increase in the prevalence of
obesity, type 2 diabetes, and CVD. West
pointedoutthatthestateofincreasedrisk
for diabetes is clearly recognizable—
today we call this risk factor clustering
metabolic syndrome. He pointed out that
type 2 diabetes is readily preventable. His
suggestion that the means to this end,
healthy lifestyle change through achieve-
ment and maintenance of a healthy body
weight and regular modest physical activ-
ity, has been convincingly proven in
many clinical trials. Rigorous epidemio-
logical studies like FHS and many others
have provided the foundation for our un-
derstandingofthenatureandmagnitudeof
theproblemathand.Whatremainsisforus
to translate that understanding into clinical
practiceandpublicpolicythatputsthatsci-
ence in the hands of patients and providers
to reverse the steadily rising tide of obesity,
type 2 diabetes, and CVD.
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